Dec 18, 2025
Back to news FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428 FORX-428 is potential new...
Aug 11, 2025
Back to news FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S.,...
Feb 17, 2025
Back to news FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer Basel, Switzerland, 26 February 2025 – FoRx Therapeutics AG, a company committed to discovering and developing innovative drugs targeting cancer-relevant DNA Damage Response (DDR)...
May 15, 2024
Back to news Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG Basel, Switzerland, 15 May 2024 – FoRx Therapeutics, an incorporated privately held company developing first-in-class compounds for cancer treatment, today announces the...
May 3, 2024
Back to news FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428 FoRx Therapeutics’ PARG – Poly(ADP-ribose) glycohydrolase – inhibitor FORX-428, a potent and selective small molecule, was nominated as...
